CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Elypta has developed a novel liquid biopsy technology that detects early-stage recurrences of Renal Cell Carcinoma through metabolite signatures in blood or urine. This approach aims to enhance patient follow-up frequency while minimizing costs and risks associated with traditional imaging methods.
Former cancer patients receive regular follow-ups to detect recurrences at early stages and optimize treatment outcomes.
The follow-up frequency is currently limited by costs and radiation risks of imaging approaches used to surveil for recurrences, resulting in recurrences being detected too late – often resulting in terminal disease.
Of the 139.000 annual Renal Cell Carcinoma (RCC) patients, 20% are diagnosed with a metastatic recurrence within 5 years after surgery.
Once metastatic, RCC survi…
ELYPTA AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
